Compounded GLP-1 ban The FDA peptides news today 2025 landscape is characterized by significant regulatory activity, particularly concerning GLP-1 receptor agonists and compounded peptides. As of 2025, the Food and Drug Administration (FDA) has been actively clarifying policies, addressing shortages, and increasing enforcement on the manufacturing and distribution of these substances. This period marks a crucial juncture for the peptide industry, with new rules reshaping its trajectory and impacting both approved medications and compounded formulations.Other safety alerts - 2026-01-14 (1)
A major focus for the FDA in 2025 has been the regulation of GLP-1 medications like semaglutide, following determinations that shortages of these injection products have been resolved. Concurrently, the agency has ramped up enforcement on compounding practices involving GLP-1s and other peptides.FDA's Overreach on Compounded Peptides: Legal Battles ... This includes issuing warning letters to entities like Pinnacle Professional Research dba Pinnacle Peptides and targeting facilities operating under 503A and 503B designations.2025年1月10日—FDAReopening Comment Period on Immunogenicity Risk of Host Cell Proteins in Follow-on RecombinantPeptideProducts. The FDA's stance aims to ensure product safety and efficacy, particularly when it comes to custom peptide medications prepared by compounding pharmacies, even for individual patient prescriptions.FDAhas identified potential significant safety risks when reviewing nominations for bulk drug substances proposed to be included on the 503A or 503B bulks ...
Despite regulatory scrutiny on compounding, 2025 has also seen positive developments in FDA approvals for peptide-based therapies.2025年4月3日—Peptidesthat can be compounded are either:FDA-approved or areFDAGRAS (Generally Recognized as Safe) status,[2] have a USP monograph, appear ... The agency approved a significant number of novel drugs, with peptides and oligonucleotides (TIDEs) representing a growing segment of these approvals. For instance, the FDA granted accelerated approval to Forzinity, a tetra-peptide for injection, and recognized the increasing value of peptide-based therapeutics, with over 80 FDA-approved drugs already on the market and more in development.2026年1月21日—The first-listed example may indicate thatFDAis relaxing the stance it took just six months ago in its July2025Warning Letter to WHOOP, Inc. Semaglutide itself has seen expanded indications, including for patients with type 2 diabetes.Pinnacle Professional Research dba Pinnacle Peptides
Understanding the current FDA compliance status for various peptide compounds is essential for both consumers and industry professionalsTheFDA's2024 approval of 50 novel drugs, including fourpeptidesand oligonucleotides (TIDEs), underscores the growing significance of these therapies in .... While the FDA has approved numerous peptides for therapeutic use, including insulin and human growth hormone, the regulatory landscape for compounded peptides is more complex.2025年5月14日—Most notable, theFDAdid not approve Novavax'speptidevaccine for SARS-CoV-2, which Makary has insisted must be tested again for efficacy. The ... The FDA has identified potential significant safety risks associated with certain bulk drug substances used in compounding. Consequently, guidance on what peptides can be compounded often hinges on whether they are FDA-approved, have GRAS (Generally Recognized as Safe) status, or possess a USP monograph.2026年1月5日—In December, the U.S. Food and Drug Administration granted fast track designations to treatments for lung, colorectal, and liver cancers, ... The agency's efforts to establish a "green list" import alert aim to protect Americans from unapproved and misbranded peptide drug products, such as those observed with semaglutide and tirzepatide from certain online vendorsOncology Drugs Fast-Tracked by the FDA in December 2025.
The peptide industry is experiencing rapid evolution, driven by advancements in drug development and increasing patient demand. The FDA's policy shifts in 2025 are reshaping the manufacturing landscape, emphasizing transparency and tightening controls. Future developments may include further clarification on product-specific guidances for generic peptide drug development and ongoing evaluation of immunogenicity risks for recombinant peptide products.FDA clarifies policies for compounders as national GLP-1 ... As the FDA continues to expand its oversight, particularly concerning 'Research Use Only' (RUO) labeling, the industry must adapt to a more stringent regulatory environment, ensuring that therapeutic peptides meet rigorous safety and efficacy standards.
Join the newsletter to receive news, updates, new products and freebies in your inbox.